Company / Free Cash Flow
Denali Therapeutics Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$422.1M
FY2025
5-year range
-$422.1M / $413.1M
FY2021-FY2025
Trend
-16.1%
vs FY2024
Sector context
#183 of 194
Health Care
What the data says
Among 194 Health Care companies, Denali Therapeutics Inc. is in the bottom 6% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from -$422M in FY2025 to $413M in FY2022.
Based on SEC 10-K filings.
-$422M in FY2025.
Declined from -$371M to -$422M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 194This company -$422.1M Sector average $470.8M
▼
-189.6% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 16.1% year-over-year.
- Ranks #183 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$422.1M | -16.1% |
| FY2024 | -$363.6M | +2.0% |
| FY2023 | -$370.9M | -189.8% |
| FY2022 | $413.1M | +343.7% |
| FY2021 | -$169.5M | -462.8% |
| FY2020 | $46.7M | +158.8% |
| FY2019 | -$79.5M | -1.9% |
| FY2018 | -$78.0M | +1.8% |
| FY2017 | -$79.5M | -1.9% |
| FY2016 | -$78.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026